Healing / tissue repair peptides
Compounds studied for tissue repair, angiogenesis, and protection — largely in animal models. Human evidence is generally limited.
S is approval-grade evidence; F is documented harm or near-zero human data. Each bar is how many peptides on this page land in that tier — a fast read on how much of this category sits in approval-grade evidence versus thin or vendor-driven claims.
The category at a glance
Every compound here ranked S–F by its weighted evidence score — strongest human / approval-grade evidence at the top, thin or vendor-driven claims at the bottom. Tap any row for the evidence read. Popularity never raises a tier.
Receipts, not vendor theater. Every tier here is computed from published evidence and regulatory status — not vendor marketing or influencer claims. See how we score.
BPentosan PolysulfateStrong human evidenceLow overstatementFDA-approved73/ 100
Pentosan polysulfate sodium (Elmiron) is FDA-approved for the bladder pain of interstitial cystitis. A landmark case series later linked chronic, multi-year exposure to a pigmentary maculopathy — a retinal safety signal that prompted FDA labelling updates.
Tier read: strong human evidence · low overstatement risk · low search interest · Approved use. Why not C: supported by human evidence, regulatory clarity. Why not A: held back by remaining gaps and limited replication.
Read the full Pentosan Polysulfate profile →DGHK CUEarly human evidenceMedium overstatementResearch-use-only45/ 100
A copper-binding tripeptide with the most evidence in topical/cosmetic skin contexts (collagen, antioxidant and regenerative signalling). Systemic/injectable human evidence is limited; much of the support is in-vitro or small skin studies. Reasonable cosmetic rationale, thin systemic data.
Tier read: early human evidence · medium overstatement risk · low search interest · Early human. Why not F: supported by preclinical depth. Why not C: held back by human evidence, regulatory clarity.
Read the full GHK CU profile →DThymosin Beta 4Early human evidenceMedium overstatementResearch-use-only40/ 100
A small actin-sequestering peptide (the parent of the TB-500 fragment) studied for tissue repair, wound healing, angiogenesis, and cardiac/corneal regeneration. Evidence is largely animal models and small early-phase trials; it is not an approved drug.
Tier read: early human evidence · medium overstatement risk · low search interest · Early human. Why not F: supported by preclinical depth. Why not C: held back by human evidence, safety clarity, regulatory clarity, practical relevance.
Read the full Thymosin Beta 4 profile →DBPC 157Early human evidenceMedium overstatementResearch-use-only39/ 100
A synthetic peptide widely marketed for healing, but the evidence is almost entirely animal and in-vitro — robust human clinical trials are lacking. It is not approved for human use and is sold research-use-only. Mechanistically interesting, clinically unproven; treat strong human claims with caution.
Tier read: early human evidence · medium overstatement risk · low search interest · Early human. Why not F: supported by preclinical depth. Why not C: held back by human evidence, safety clarity, regulatory clarity.
Read the full BPC 157 profile →FTB 500Early human evidenceMedium overstatementResearch-use-only30/ 100
TB-500 is a synthetic fragment related to thymosin β4. Thymosin β4 has been studied preclinically for wound and tissue repair, but TB-500 itself has minimal human evidence and is not approved. Most claims rest on animal data.
Tier read: early human evidence · medium overstatement risk · low search interest · Animal. Why not D: held back by human evidence, safety clarity, regulatory clarity, practical relevance.
Read the full TB 500 profile →Tissue-repair peptides are where the hype-to-evidence gap is widest. Compounds like BPC-157 and TB-500 dominate recovery forums, but their support is overwhelmingly preclinical — animal models and mechanism — with little rigorous human evidence behind the popular injury-recovery claims.
Start with the best-supported options: Pentosan Polysulfate. Then compare them before exploring research-only compounds.
Nothing in this bucket.
Nothing in this bucket.
What the evidence actually supports
BPC-157, TB-500, and thymosin beta-4 show repair-relevant signals (angiogenesis, cell migration, actin regulation) mainly in animal studies. GHK-Cu has the most support for skin/wound contexts, largely topical. None of these has a robust base of controlled human trials for tendon, ligament, or general injury recovery.
Where the hype outruns the data
“Heals tendons,” “fixes your gut,” and “faster recovery for everyone” run far ahead of the human data. These are research-only compounds; long-term human safety isn't established, and sourcing/purity from non-pharmaceutical material is an added risk. Promising in a rat ≠ proven in a person.
FAQ
Does BPC-157 heal injuries in humans?
There's no robust human clinical evidence supporting the popular tendon/injury-recovery claims — the repair signals come mainly from animal models.
Is there a strong human-evidence option for healing?
Not broadly. No tissue-repair peptide here has strong human trials; the category is early. The goal page buckets show which are merely “worth watching” vs. “too early.”
Is this medical advice?
No — research reference only. No dosing or protocols.
Research reference only. Not medical advice, treatment instructions, or a purchase recommendation. Consult a licensed professional.